PlantEXT

Developer of cannabis-based medical products targeting inflammation-related conditions.

Health Tech & Life Sciences
Active
Seed Herzliya, Israel Founded 2015
Last updated 2026-07-26
Total raised
$5.6M
Last: Undisclosed Round 2019-04
Stage
Seed
Founded
2015
Headcount
7
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences

About

PlantEXT is an Israeli and Canadian company focused on developing science-based medical cannabis formulations. They leverage proprietary technology and research agreements with institutions like Israel's Agricultural Research Organization (ARO) to identify synergistic combinations of cannabinoids and terpenes for anti-inflammatory treatments. Their pipeline includes products for conditions such as Inflammatory Bowel Disease (IBD), psoriasis, atopic dermatitis, arthritis, pain, and migraines. PlantEXT is a pharmaceutical cannabis research and product development company led by R&D and product commercialization experts. The company's approach to development is based on knowledge and experience in the pharmaceutical industry, utilizing a systematic approach to medical cannabis development in tandem with the pharmaceutical Quality by Design approach (QbD).

Funding history · 3 rounds · $5.6M total

2019-03
Seed Extension $1.2M
2018-03
Seed Extension $2.4M
2018-01
Seed $2.0M

Headcount over time

From 9 (2018-08) to 7 (2023-03) · -2 (-22%) · 15 points · source: Finder history + radar grounding
110 2018-08 2023-03

Q&A

What is PlantEXT's primary focus?
PlantEXT is an Israeli and Canadian company focused on developing science-based medical cannabis formulations, specifically targeting inflammation-related conditions.
What is PlantEXT's total funding to date?
PlantEXT has raised a total of $5.6 million USD across multiple funding rounds.
Who is the CEO of PlantEXT?
Willy Kruh was appointed as the Chief Executive Officer of PlantEXT in October 2020.
What was PlantEXT's most recent funding round?
In April 2019, PlantEXT completed a Seed round, raising $1.2 million USD. Beacon Securities Limited was among the investors.
What research collaborations does PlantEXT have?
PlantEXT has a research agreement with Israel's Agricultural Research Organization (ARO) to identify synergistic combinations of cannabinoids and terpenes for anti-inflammatory treatments.
What types of conditions does PlantEXT's product pipeline target?
PlantEXT's pipeline includes products for conditions such as Inflammatory Bowel Disease (IBD), psoriasis, atopic dermatitis, arthritis, pain, and migraines.

Team · 1

Oded Sagee
Founder · Founder, Director, President - Israel

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical CannabisDrugs Discovery & Development
Technologies
BiologicalsMoleculesHerbals
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 Patents

Tags

pharmaceuticalstherapeuticsmedical-cannabispain-reliefchronic-patientstopical-treatmentcannabisanti-inflammatorydermatologypatients
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteplantext.com/
LinkedInlinkedin.com/company/17901135
Facebookfacebook.com/Plantext-2334608700196085

Identifiers & details

Legal namePlantEXT Ltd.
Founded2015
Employees (exact)7
OfficesToronto

Radar intelligence

Web history (Wayback)

Domainplantext.com

Certificate / subdomain footprint

Subdomains3

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)515356384
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2015-12-15
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)yes
Last annual report2018
Active charges / liens0
Registry events0
Registered addressשד' אלי לנדאו 50 הרצליה